Why is this effective HSP90 inhibitor not being developed in HER2+ breast cancer?
Why is this effective HSP90 inhibitor not being developed in HER2+ breast cancer?
复制标题
DOI：
10.1158/1078-0432.ccr-11-1218
复制
发表时间：
2011-08-01
期刊：
影响因子：
--
通讯作者：
Arteaga CL
中科院分区：
文献类型：
--
作者：
Arteaga CL
抑制HSP 90伴侣蛋白导致HER2受体降解。HSP90抑制剂tanespimycin联合曲妥珠单抗在HER2过表达转移性乳腺癌患者中具有活性。这种组合是几种HER2靶向疗法之一，将显著改善这种亚型乳腺癌患者的预后。
Inhibition of the HSP90 chaperone leads to degradation of the HER2 receptor. The HSP90 inhibitor tanespimycin in combination with trastuzumab is active in patients with HER2-overexpressing metastatic breast cancer. This combination is one of several HER2-targeted therapies that will significantly improve the outcome of patients with this subtype of breast cancer.